Marie-Anne Goyette

Marie-Anne Goyette uses unique metastasis models and in vivo models to study the HER2 oncogene and glycosylation in breast cancer progression. Her highly promising research program will focus in particular on identifying mechanisms of resistance and therapeutic adaptation. Her dual expertise in metastasis biology and glycosylation complements that of several researchers at IRIC and within the Department.

Before joining IRIC, she completed a postdoctoral fellowship at the Dana-Farber Cancer Institute, affiliated with Harvard Medical School in Boston. She had previously earned her Ph.D. from the University of Montreal, completed at the Montreal Clinical Research Institute.

Principal Investigator, Tumor Heterogeneity and Metastasis Research Unit, IRIC

Assistant Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal

Tumor Heterogeneity and Metastasis Research Unit
Marcelle-Coutu Pavilion, 3306-3
Social networks

Apply for a M.Sc. or a Ph.D.

Tumor Heterogeneity and Metastasis

Marie-Anne Goyette and her team are studying the heterogeneity of breast cancer, which underlies the development of lethal metastases and resistance to treatment. Their research focuses on potential therapeutic vulnerabilities, resistance mechanisms, and the metastatic characteristics of heterogeneous tumors. To this end, the team uses in vitro and in vivo breast cancer models in mice, in combination with cutting-edge techniques including scRNA-seq, proteomics, and pharmacological and genomic screens.

IRIC - Institute for Research in Immunology and Cancer

Tumor Heterogeneity and Metastasis

Research topics

Targeted Therapy and Diagnostics